News

In this week’s Pointers With Portela, the 208SkinDoc reviews a patient case of topical steroid withdrawal.

The analyses were published in the Journal of the European Academy of Dermatology and Venereology.

The study examined the mechanisms of action associated with immune checkpoint inhibitor combination therapies.

The most prevalent psychological disorder among patients was anxiety.

Learn more about the in-depth topics covered in the December 2023 print issue of Dermatology Times.

The study findings were presented in a poster at the 2023 Revolutionizing Atopic Dermatitis Virtual Conference.

Researchers observed lower levels of serum gamma linolenic acid in patients with rosacea.

Delve into challenging vitiligo cases and solutions discussed at recent Dermatology Times Case Based Roundtable events across the country.

Investigators evaluated vitiligo punch grafting effectiveness on stable vitiligo lesions.

Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.

Dr Derm has recently been sued by a patient for simply asking the question “Do you own a gun?” He seeks legal advice.

Sarkar spoke with Dermatology Times after the ReV conference to discuss her session on vitiligo stigma.

Delve into challenging vitiligo cases and solutions discussed at recent Dermatology Times Case Based Roundtable events across the country.

Tapinarof is showing promise in the landscape of dermatological treatment. Adelaide Hebert, MD, FAAD, recently served as an investigator for 2 studies presented at the European Academy of Dermatology and Venereology (EADV) Congress and discussed key points with Raj Chovatiya, MD, PhD.

Read the top 10 takeaways from a recent discussion among experts in the management of plaque psoriasis.

Aesthetic procedures for patients with skin of color necessitate a nuanced approach that prioritizes patient safety and optimal outcomes.

Check out these 5 factors that can significantly impact a dermatologist’s financial plan and should therefore incorporate flexibility and resiliency to structure the plan for long-term success.

Chiesi Global Rare Diseases recently announced the approval of the topical treatment.

Nanette Silverberg, MD, takes a deep dive into the importance of early intervention and gave an overview of topical care for patients of all ages with vitiligo.

Roundtable participants shared 10 different considerations to make for a patient, like this 23-year old woman, with a new environment and lifestyle.

The Society for Immunotherapy of Cancer recently published insights into the management of patients with preexisting autoimmune disease, solid organ transplant recipients, elderly individuals, those living with HIV, pregnant patients, and those with rare noncutaneous subtypes of melanoma.

Lisa Swanson, MD, FAAD, and Robert Casquejo, PA-C, discuss their preferred treatment approach for plaque psoriasis, which includes PDE4 inhibitors such as apremilast and roflumilast.

Click here to answer this week's poll about a recent FDA Complete Response Letter.

Review a rundown of our top articles and resources for patients inspired by National Eczema Awareness Month.

A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.

Pusan National University published the review in light of the growing body of JAK inhibitors in the AD space.

At 3 years, V940 plus pembrolizumab reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%.

Keep up with the latest headlines in dermatology from the past week, including a new immuno-dermatology partnership, promising study results from a combined mRNA vaccine and Keytruda for advanced melanoma, and more.

Here is a recap of the drugs and treatments approved to keep in mind for the new year.

ICYMI, this week we had articles about coverage from the Revolutionizing Atopic Dermatitis and Vitiligo virtual conferences, expert insights on AAD's updated AD management guidelines, positive data of axitinib for basal cell carcinoma, and more.